Defunct Company
Total Trials
6
As Lead Sponsor
As Collaborator
0
Total Enrollment
695
NCT02807558
A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase: Phase 2
Role: Lead Sponsor
Start: Sep 20, 2016
Completion: Jan 25, 2023
NCT03134638
A Study of SY-1365 in Adult Patients With Advanced Solid Tumors
Phase: Phase 1
Start: May 12, 2017
Completion: Jun 24, 2020
NCT04247126
A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors
Start: Jan 23, 2020
Completion: Mar 30, 2023
NCT04797780
Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome
Phase: Phase 3
Start: Feb 8, 2021
Completion: Nov 13, 2024
NCT04905407
Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Start: Aug 26, 2021
Completion: Aug 12, 2024
NCT04996030
A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia
Start: Sep 17, 2021
Completion: Apr 30, 2024